SCHEMBL27218673

SCHEMBL27218673

Cc1cc(N)nc(SCc2nc(COc3ccc(F)cc3)no2)n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 6/20 0.46
▸ NPC1 O15118 5/20 0.46
▸ SMN1; SMN2 Q16637 3/20 0.46
▸ HTT P42858 2/20 0.46
▸ LMNA P02545 2/20 0.46
▸ DCK P27707 3/20 0.40
▸ TDP1 Q9NUW8 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ MEN1 O00255 3/20 0.38
▸ KMT2A Q03164 3/20 0.38
▸ ALDH1A1 P00352 2/20 0.37
▸ HPGD P15428 1/20 0.37
▸ MAPT P10636 2/20 0.37
▸ CYP2C9 P11712 1/20 0.37
▸ CYP2C19 P33261 1/20 0.37
▸ HSD17B10 Q99714 1/20 0.37
▸ THRB P10828 1/20 0.37
▸ TNKS2 Q9H2K2 1/20 0.37
▸ FFAR1 O14842 1/20 0.35
▸ PPARG P37231 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31494455 0.86 RAB9A (0.48) RAB9ANPC1SMN1; SMN2HTTLMNA
SCHEMBL27218748 0.82 RAB9A (0.50) RAB9ANPC1SMN1; SMN2HTTLMNA
SCHEMBL31528335 0.82 RAB9A (0.50) RAB9ANPC1SMN1; SMN2HTTLMNA
SCHEMBL27218782 0.79 RAB9A (0.47) RAB9ANPC1SMN1; SMN2HTTLMNA
SCHEMBL27218708 0.77 RAB9A (0.49) RAB9ANPC1SMN1; SMN2HTTLMNA
SCHEMBL27218817 0.75 RAB9A (0.50) RAB9ANPC1SMN1; SMN2HTTLMNA
SCHEMBL27218874 0.73 HTT (0.69) RAB9ANPC1SMN1; SMN2HTTLMNA
SCHEMBL27218663 0.73 LMNA (0.62) RAB9ANPC1SMN1; SMN2HTTLMNA
SCHEMBL31494346 0.72 ALDH1A1 (0.49) RAB9ANPC1SMN1; SMN2HTTLMNA
SCHEMBL27218845 0.72 ALDH1A1 (0.49) RAB9ANPC1SMN1; SMN2HTTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4232448-B1 AGONISTS OF FREE FATTY ACID RECEPTOR 1 AND THEIR USE IN DISEASES ASSOCIATED WITH SAID RECEPTOR Halo Therapeutics Ltd (GB) 2025-05-07 — — EP disclosed
EP-3956323-B1 OXAZOLE AND OXADIAZOLE DERIVATIVES USEFUL AS AGONISTS OF FREE FATTY ACID RECEPTOR 1 Halo Therapeutics Ltd (GB) 2025-03-05 — — EP disclosed
US-20240158382-A1 Agonists Of Free Fatty Acid Receptor 1 And Their Use In Diseases Associated With Said Receptor Halo Therapeutics Ltd (GB) 2024-05-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240158382-A1 Agonists Of Free Fatty Acid Receptor 1 And Their Use In Diseases Associated With Said Receptor FFAR1, FFAR2, FFAR3 RAB9A 2474/4885NPC1 781/4885SMN1; SMN2 1802/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback